×
NewAmsterdam Pharma Price to Free Cash Flow Ratio 2021-2024 | NAMS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
NewAmsterdam Pharma price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
View More
NewAmsterdam Pharma Price to Free Cash Flow Ratio 2021-2024 | NAMS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
NewAmsterdam Pharma price to free cash flow ratio from 2021 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$76.9B
Takeda Pharmaceutical (TAK)
$43.9B
Merck (MKKGY)
$20.8B
Astellas Pharma (ALPMY)
$20.2B
Sandoz Group AG (SDZNY)
$19.6B
United Therapeutics (UTHR)
$17.7B
Summit Therapeutics (SMMT)
$15.4B
Neurocrine Biosciences (NBIX)
$12.7B
Shionogi (SGIOY)
$12.3B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$5.7B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.7B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$3B
Catalyst Pharmaceuticals (CPRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Soleno Therapeutics (SLNO)
$2.2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.7B
Ocular Therapeutix (OCUL)
$1.7B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Ardelyx (ARDX)
$1.5B
ARS Pharmaceuticals (SPRY)
$1.5B